Skip to content Skip to footer
Subscribe Now
PharmaShots Interview Jon Heinrichs of Sanofi Pasteur & Tonya Villafana of AstraZeneca Shares Insights on Nirsevimab in Healthy Infants Born at Term or Late Preterm
VIEWPOINTS

PharmaShots Interview: Jon Heinrichs of Sanofi Pasteur & Tonya Villafana of AstraZeneca Shares Insights on Nirsevimab in Healthy Infants Born at Term or Late Preterm

In an interview with PharmaShots, Jon Heinrichs, Associate, Vice President, and the Head of Innovation and Emerging Sciences at Sanofi Pasteur & Tonya Villafana, Vice President, Global Franchise Head, Infection at AstraZeneca share their views on the data of Nirsevimab in P-III (MELODY) trial to protect infants against Respiratory Syncytial Virus Shots: The P-III (MELODY) trial evaluates nirsevimab (50/100mg, IM) vs…
April 19, 2022

Read more

PharmaShots Interview Reproductive Solutions’ Diana Peninger Shares Insights on ProteX, a Solution for Male Infertility
VIEWPOINTS

PharmaShots Interview: Reproductive Solutions’ Diana Peninger Shares Insights on ProteX, a Solution for Male Infertility

In an interview with PharmaShots, Diana Peninger, President and CEO at Reproductive Solutions shares her views on the ProteX sperm collection solution, offering a new hope for infertile couples. Shots: Reproductive Solutions (RSI) reported the availability of a patented, FDA-listed semen collection container that improves specimen quality for in vitro fertilization and other assisted reproductive technologies The ProteX container…
April 18, 2022

Read more

Disease of the Month: Chagas Disease (American Trypanosomiasis)
INSIGHTS+

Disease of the Month: Chagas Disease (American Trypanosomiasis)

INTRODUCTION Chagas disease also known by the name American trypanosomiasis, is a zoonotic infection, caused by protozoan flagellate Trypanosoma cruzi (kissing bugs). It is potentially a life-threatening infection transmitted to people and animals from the feces of blood-sucking bugs which belong to the subfamily of Triatominae2. Among all the vectors, Rhodnius proxilus, Panstrongylus megistus, and…
April 14, 2022

Read more

PharmaShots Interview Fountain Therapeutics’ William Greene Shares Insights on the $15M Series A-2 Financing
VIEWPOINTS

PharmaShots Interview: Fountain Therapeutics’ William Greene Shares Insights on the $15M Series A-2 Financing

In an interview with PharmaShots, William Greene, CEO at Fountain Therapeutics shares his views on the closing of $15M Series A-2 financing & how it supports the drug discovery platform and pipeline Shots: The company closes $15M series A-2 financing bringing its total Series A funding to $26M which was led by Eli Lilly, Alexandria Venture Investments, and R42 Group as new…
April 13, 2022

Read more

PharmaShots Interview Medidata’s Kelly McKee Shares Insight on Decentralized Clinical Trial
VIEWPOINTS

PharmaShots Interview: Medidata’s Kelly McKee Shares Insight on Decentralized Clinical Trial

In an interview with PharmaShots, Kelly McKee, Vice President, Patient Registries & Recruitment at Medidata shared her views on the decentralized clinical trial networks through the collaboration with Circuit Clinical Shots: Medidata is investing $27M in Circuit Clinical’s series C funding. Circuit Clinical will expand its DCT network to 500 physicians & 15M patients & bring clinical research as…
April 12, 2022

Read more

PharmaShots Interview Abbott’s Allen Burton Shares Insight on Proclaim XR Spinal Cord Stimulation System for the Treatment of Chronic Intractable Pain of Trunk and Limbs
VIEWPOINTS

PharmaShots Interview: Abbott’s Allen Burton Shares Insight on Proclaim XR Spinal Cord Stimulation System for the Treatment of Chronic Intractable Pain of Trunk and Limbs

In an interview with PharmaShots, Dr. Allen Burton, Medical Director of Abbott’s Neuromodulation Business shared his views on the US FDA approval for expanded MRI compatibility of Its Proclaim XR SCS Device Shots: The US FDA has approved new expanded MRI compatibility for its Proclaim XR Spinal Cord Stimulation (SCS) System with Octrode leads. The Proclaim XR SCS System is an…
April 11, 2022

Read more

Insights+ Key Biosimilars Events of March 2022
INSIGHTS+

Insights+ Key Biosimilars Events of March 2022

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients During the month of March, Junshi & Mabwell Bioscience’s Junmaikang (biosimilar, adalimumab)…
April 7, 2022

Read more

PharmaShots Interview SOTIO Richard Sachse Shares Insight on SOT101 for the Treatment of Advanced Metastatic Solid Tumors
VIEWPOINTS

PharmaShots Interview: SOTIO’ Richard Sachse Shares Insight on SOT101 for the Treatment of Advanced/Metastatic Solid Tumors

In an interview with PharmaShots, Richard Sachse, Chief Medical Officer & Managing Director at SOTIO shared his views on the data of SOT101 in the P-I/Ib (AURELIO-03) study for the treatment of advanced/metastatic solid tumors Shots: The P-I/Ib (AURELIO-03) study evaluates SOT101 as monothx. & in combination with pembrolizumab in patients with advanced/metastatic solid tumors The results showed that 13 patients…
April 6, 2022

Read more

PharmaShots Interview Ikena Oncology’ Mark Manfredi Shares Insight on IK-930 for the Treatment of Solid Tumors
VIEWPOINTS

PharmaShots Interview: Ikena Oncology’ Mark Manfredi Shares Insight on IK-930 for the Treatment of Solid Tumors

In an interview with PharmaShots, Mark Manfredi, President, and CEO at Ikena Oncology shared his views on the US FDA’s IND clearance of IK-930 for the treatment of solid tumors that harbors genetic alterations in the hippo pathway Shots: The US FDA has accepted its IND application to initiate the P-I study of IK-930 for solid tumors harboring genetic alterations in the…
April 5, 2022

Read more

PharmaShots Interview Frank Leebeek & Greta Mulder of Erasmus MC, Lutz Bonacker of CSL Behring Share Insight on Etranacogene Dezaparvovec for the Treatment of Hemophilia B
VIEWPOINTS

PharmaShots Interview: Frank Leebeek & Greta Mulder of Erasmus MC, Lutz Bonacker of CSL Behring Share Insight on Etranacogene Dezaparvovec for the Treatment of Hemophilia B

In an interview with PharmaShots, Frank Leebeek, MD, Ph.D., Hematology Department Head & Greta Mulders, Nurse Practitioner, Study Coordinator at the Erasmus Medical Center in Rotterdam, Lutz Bonacker, Senior Vice President, General Manager, Commercial Operations Europe at CSL Behring shared their views on the data of Etranacogene Dezaparvovec in P-III (HOPE-B) trial for the treatment of Hemophilia B, presented at EAHAD 2022…
April 4, 2022

Read more

Load more